Tapazole, Methimazole News

This Article is provided free of charge. Add to File Drawer DRUG WATCH: Treatment for Graves' Disease Poses Risk of Liver Failure Abstract * Propylthiouracil, used in the treatment of Graves' disease, can increase the risk of serious liver injury, including liver failure and death.

Lily, a mature black-and-white feline, meowed constantly and ate voraciously yet never seemed to gain weight.

Kenneth D. Burman, MD, chief of the Endocrine Section at the Washington Hospital Center, Washington, DC and professor in the Department of Medicine at Georgetown University, will outline the risks and benefits of anti-thyroid drugs Sunday September 27 at 9 a.m. when he speaks at the American Thyroid Association's 80th Annual Meeting September ...

Dear Daisy Dog: How long can I safely leave my dog in the car, assuming the windows are partially open? Please answer with the number of minutes, depending on whether my car is parked in the sun or shade, and the outside air temperature is 60 through 75 degrees.

The FDA has reported on at least 32 cases of serious liver damage associated with the use of propylthiouracil in adults and children, including twelve deaths and five liver transplants in adults, and one death and six liver transplants in pediatric patients.

The U.S. Food and Drug Administration warned health care professionals about the risk of serious liver injury associated with the use of the anti-thyroid drug propylthiouracil for the treatment of Graves' disease.

The Federal Drug Administration approved a drug to treat hyperthyroidism in cats.

The FDA is warning physicians about the risks of liver injury, including liver failure and death, associated with the use of propylthiouracil.

The U.S. Food and Drug Administration has issued a safety alert for the antithyroid drug propylthiouracil , which is used to treat hyperthyroidism -- an overactive thyroid.

FDA notified healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil in adult and pediatric patients.

The U.S. Food and Drug Administration today warned health care professionals about the risk of serious liver injury associated with the use of the anti-thyroid drug propylthiouracil for the treatment of Graves' disease.